Developer docs
API playgroundTry for free, no card

Search company profiles

Medtech AI

Full company profile

uuid000x9dd

Namestring
Medtech AI
Legal namestring
MedTechAI Inc.
Websiteurl
medtechai.io
Company typeenum
Private
Founded yearstring
-
Descriptiontext

MedTechAI Inc. is a Toronto-based private company that operates as the financing and commercialization arm of Oxford Immune Algorithmics (OIA), holding 28% of OIA with stated intent to increase its stake to 38%. The company is built around Algocyte, a handheld finger-prick-based diagnostic device co-developed with the UK National Health System, paired with a portable web-based platform that applies causal predictive AI algorithms to immune-system data to enable early detection of more than 20 health conditions and to deliver personalized, predictive medicine. The core technology is described as proprietary causal predictive modeling capable of outperforming generic machine learning on complex biological systems with limited data; the same algorithmic core was externally validated by winning Etihad's AI International Competition (run with HUB71 and Accenture) at 90%+ accuracy on cash-flow prediction, and the company has been invited to deploy it at Etihad Aviation Group scale.

MedTechAI goes to market through enterprise field sales supported by a network of regional hub and channel partners: HUB71 in the UAE for Asia/Africa/Middle East, Creative Destruction Lab in the US, SpinLab in Germany for the EU, Lacuna Diagnostics in China and the US, a UK hematology market leader controlling approximately one-third of the UK hematology market, and a Surrey smart-home developer for residential pilots. Reported commercial milestones to date consist of Letters of Intent rather than executed purchase orders — most notably a 3,000-device LOI from Lacuna Diagnostics China covering 1,000 hospitals with 600+ million annual patient visits, and integration terms with Lacuna Diagnostics US across 40 hospitals. The company has not disclosed revenue or product shipments.

Revenue mechanics combine hardware sales of the Algocyte device with potential subscription or platform recurring revenue from the web-based monitoring layer. Pricing is not publicly disclosed; the model is enterprise-channel driven rather than self-serve. Governance includes John Cullen as CEO, Andres Tinajero as CFO, Allan Bezanson as Director, and Pamela Winsor (former CMO of Medtronic) as Chair. The firm has been recognized as one of the 50 Most Promising Game-Changers in the Thames Valley (2020), nominated for the OBN Best Start-up Medtech Award (2020), and its underlying OIA technology won the Etihad AI International Competition in March 2021.

Short descriptiontext

MedTechAI Inc. is a Toronto-based financing and commercialization vehicle for Oxford Immune Algorithmics, deploying the Algocyte handheld finger-prick diagnostic device and a causal predictive AI platform for early disease detection across hospital networks, smart-home pilots, and enterprise partners in the UK, UAE, US, China, and Germany.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical diagnostic devices, immune health monitoring, predictive healthcare analytics, handheld diagnostic technology, AI medical diagnostics
Industry2 codes
PRIMARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Diagnostic Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Algocyte Device Sales
TypeHardware Sales
Description

Revenue from sale of handheld diagnostic devices (Algocyte) for early disease detection and immune health monitoring.

medtechai.io
2Platform/Subscription Services
TypeSubscription Recurring
Description

Ongoing revenue from web-based platform access for immune system monitoring and predictive diagnostics, potentially subscription-based for continuous health monitoring services.

medtechai.io
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Algocyte
Description

Handheld finger-prick-based device for rapid early detection of health diseases and conditions, co-developed with the UK National Health System (NHS). The device monitors and learns from the immune system to deliver personalized and predictive medicine.

medtechai.io
Core offering1 text field

MedTechAI commercializes the Algocyte handheld finger-prick diagnostic device co-developed with the UK NHS, paired with a portable web-based AI platform that monitors the user's immune system for rapid early detection of over 20 health diseases and conditions. The system delivers personalized and predictive medicine via causal predictive algorithms originated at Karolinska, incubated at the University of Oxford, and co-developed with the University of Cambridge.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 90%+ accuracy in predicting unpublished data compared to actual time series data
+2 more records
Product overview1 text field

MedTechAI offers a single unified product portfolio centered on Algocyte, a handheld finger-prick-based diagnostic device co-developed with the UK National Health System (NHS). The device is supported by a portable web-based platform that uses AI algorithms to deliver personalized and predictive medicine by learning from and monitoring the user's immune system for early disease detection.

Product and service1 record
1Algocyte Diagnostic Device and Platform
CategoryMedical diagnostic devices and AI-powered immune health monitoring platform
Description

A handheld finger-prick-based device co-developed with the UK NHS that enables rapid early detection of over 20 health diseases and conditions by monitoring and learning from the user's immune system, paired with a portable web-based AI platform for personalized and predictive medicine. Designed for healthcare providers, diagnostic labs, hospital networks, and public health systems.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NHS co-developed and tested the Algocyte handheld finger-prick diagnostic device. This partnership provides regulatory validation and clinical testing environment for the immune health monitoring platform.

2UK Hematology Market Leader
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

UK reseller partner and leader in the hematology market in the UK, holding approximately 1/3 of the market share. This partnership provides established distribution channels in the UK healthcare market.

medtechai.io
3Surrey Intelligent Home System
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Ten houses to open in Q1 2021 in Surrey with Algocyte embedded in the intelligent home system, representing integration of health monitoring into residential environments.

medtechai.io
Strategic tierMajorTypeStrategic or Co-development Partner
Description

OIA UAE branch sponsored by UAE committed to invest and grow the company as a hub for Asia, Africa and the Middle East. Signed collaboration agreement with medical university (KIC). This represents a major international expansion initiative.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

OIA was among 3 finalists among 400 startups in Creative Destruction Lab's US program. Medtech AI issued Letter of Intent to invest up to $6M in OIA over the next 2 years. Pam Winsor, CMO of Medtronic, joining the board.

6Lacuna Diagnostics (China)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Leading IT remote/mobile healthcare solution provider in China covering 1,000 hospitals with over 600 million patient visits per year and 1.5 million doctors. Letter of Intent signed requesting 3,000 devices initially.

medtechai.io
7Lacuna Diagnostics (US)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Servicing 40 hospitals in the US. Terms agreed to integrate Algocyte in their pathology pathway offerings.

medtechai.io
Strategic tierMinorTypeStrategic or Co-development Partner
Description

SpinLab's and Leipzig's commercial partners and support to open European branch. Agreement with the Leipzig zoo to test technology applied to veterinary applications.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Medical university in UAE with signed collaboration agreement, part of the HUB71 hub ecosystem for Asia, Africa and Middle East expansion.

10Etihad Group Finance
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Etihad Group Finance (owner of Etihad Airlines) held AI international competition with partners HUB71 and Accenture. OIA won the competition and will implement forecasting platform for Etihad's Aviation Group at global scale. Prize of $10,000 USD awarded.

medtechai.io
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Tasso produces at-home blood-collection devices paired with remote lab testing, addressing the same workflow as Algocyte — patient-friendly capillary sampling followed by connected diagnostic processing.

TypeDirect peer
Description

Healthy.io turns smartphone cameras into clinical-grade diagnostic readers (e.g., urinalysis, wound care). It is comparable to Algocyte in delivering clinical-grade diagnostics through a consumer/patient-friendly connected device format.

3Cue Health
TypeDirect peer
Description

Cue Health builds a handheld molecular diagnostic device for at-home and clinical use, with a portable reader and connected platform. It is the closest publicly comparable to Algocyte in form factor, connected-diagnostics business model, and enterprise-plus-consumer GTM.

TypeDirect peer
Description

Everlywell offers at-home sample collection kits with connected lab testing for a panel of conditions. It competes with Algocyte on multi-condition at-home diagnostics, though Everlywell relies on mailed samples rather than an in-home reader.

TypeDirect peer
Description

Babson has developed a finger-prick blood collection and diagnostics ecosystem aimed at retail and clinical settings. It competes with Algocyte on miniaturization of blood-based diagnostics and on retail/clinical partnerships.

TypeDirect peer
Description

Yourbio Health (formerly Seventh Sense Biosystems) developed the TAP device for virtually painless capillary blood collection, targeting decentralized diagnostics and remote clinical trials — overlapping with Algocyte's finger-prick remote-diagnostic value proposition.

TypeBroad incumbent
Description

Roche Diagnostics is a global leader in clinical diagnostics, including POC and immunoassay platforms. It is a broad incumbent with overlapping capability in immune and infectious-disease testing that Algocyte must compete against or partner with for hospital adoption.

TypeEmerging player
Description

SiPhox Health is building an at-home protein and hormone diagnostic platform with a connected reader. It targets a similar multi-biomarker home-diagnostic thesis to Algocyte, though at an earlier stage of commercialization.

TypeDirect peer
Description

OIA is the operating company that created Algocyte and the scientific entity in which MedTechAI holds a 28% stake. It is the most direct comparable because the underlying technology, product, and pipeline are the same; MedTechAI is essentially an investment vehicle into OIA.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott Diagnostics offers extensive POC and immunoassay product lines (e.g., i-STAT, Binax) and deep hospital distribution globally. It represents the type of entrenched incumbent MedTechAI/OIA must displace or co-exist with in the POC diagnostics market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medtech AI

Medical Diagnostic Devicesmedtechai.io

MedTechAI Inc. is a Toronto-based financing and commercialization vehicle for Oxford Immune Algorithmics, deploying the Algocyte handheld finger-prick diagnostic device and a causal predictive AI platform for early disease detection across hospital networks, smart-home pilots, and enterprise partners in the UK, UAE, US, China, and Germany.

What Medtech AI does

MedTechAI Inc. is a Toronto-based private company that operates as the financing and commercialization arm of Oxford Immune Algorithmics (OIA), holding 28% of OIA with stated intent to increase its stake to 38%. The company is built around Algocyte, a handheld finger-prick-based diagnostic device co-developed with the UK National Health System, paired with a portable web-based platform that applies causal predictive AI algorithms to immune-system data to enable early detection of more than 20 health conditions and to deliver personalized, predictive medicine. The core technology is described as proprietary causal predictive modeling capable of outperforming generic machine learning on complex biological systems with limited data; the same algorithmic core was externally validated by winning Etihad's AI International Competition (run with HUB71 and Accenture) at 90%+ accuracy on cash-flow prediction, and the company has been invited to deploy it at Etihad Aviation Group scale.

MedTechAI goes to market through enterprise field sales supported by a network of regional hub and channel partners: HUB71 in the UAE for Asia/Africa/Middle East, Creative Destruction Lab in the US, SpinLab in Germany for the EU, Lacuna Diagnostics in China and the US, a UK hematology market leader controlling approximately one-third of the UK hematology market, and a Surrey smart-home developer for residential pilots. Reported commercial milestones to date consist of Letters of Intent rather than executed purchase orders — most notably a 3,000-device LOI from Lacuna Diagnostics China covering 1,000 hospitals with 600+ million annual patient visits, and integration terms with Lacuna Diagnostics US across 40 hospitals. The company has not disclosed revenue or product shipments.

Revenue mechanics combine hardware sales of the Algocyte device with potential subscription or platform recurring revenue from the web-based monitoring layer. Pricing is not publicly disclosed; the model is enterprise-channel driven rather than self-serve. Governance includes John Cullen as CEO, Andres Tinajero as CFO, Allan Bezanson as Director, and Pamela Winsor (former CMO of Medtronic) as Chair. The firm has been recognized as one of the 50 Most Promising Game-Changers in the Thames Valley (2020), nominated for the OBN Best Start-up Medtech Award (2020), and its underlying OIA technology won the Etihad AI International Competition in March 2021.

Medtech AI firmographics

Firmographics
Name
Medtech AI
Legal name
MedTechAI Inc.
Website
https://medtechai.io
Company type
Private
Operating status
Operating
Short description
MedTechAI Inc. is a Toronto-based financing and commercialization vehicle for Oxford Immune Algorithmics, deploying the Algocyte handheld finger-prick diagnostic device and a causal predictive AI platform for early disease detection across hospital networks, smart-home pilots, and enterprise partners in the UK, UAE, US, China, and Germany.
Ownership category
akta.pro rank

Medtech AI industry classification

Industry
Product category
Medical Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Medical diagnostic devices
  • Immune health monitoring
  • Predictive healthcare analytics
  • Handheld diagnostic technology
  • AI medical diagnostics

Where Medtech AI is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices3 records

Markets served

Medtech AI business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Algocyte Device Sales: Revenue from sale of handheld diagnostic devices (Algocyte) for early disease detection and immune health monitoring.
  2. Platform/Subscription Services: Ongoing revenue from web-based platform access for immune system monitoring and predictive diagnostics, potentially subscription-based for continuous health monitoring services.

Go-to-market motion1 record

Distribution channels7 records

Marketing channels3 records

Medtech AI product offering

Product offering

Core offering

MedTechAI commercializes the Algocyte handheld finger-prick diagnostic device co-developed with the UK NHS, paired with a portable web-based AI platform that monitors the user's immune system for rapid early detection of over 20 health diseases and conditions. The system delivers personalized and predictive medicine via causal predictive algorithms originated at Karolinska, incubated at the University of Oxford, and co-developed with the University of Cambridge.

Product overview

MedTechAI offers a single unified product portfolio centered on Algocyte, a handheld finger-prick-based diagnostic device co-developed with the UK National Health System (NHS). The device is supported by a portable web-based platform that uses AI algorithms to deliver personalized and predictive medicine by learning from and monitoring the user's immune system for early disease detection.

Differentiator

Problem solved

Functional benefit

Brands

  • Algocyte: Handheld finger-prick-based device for rapid early detection of health diseases and conditions, co-developed with the UK National Health System (NHS). The device monitors and learns from the immune system to deliver personalized and predictive medicine.

Products and services

  • Algocyte Diagnostic Device and Platform A handheld finger-prick-based device co-developed with the UK NHS that enables rapid early detection of over 20 health diseases and conditions by monitoring and learning from the user's immune system, paired with a portable web-based AI platform for personalized and predictive medicine. Designed for healthcare providers, diagnostic labs, hospital networks, and public health systems.

Quantifiable outcome

  • 90%+ accuracy in predicting unpublished data compared to actual time series data
  • +2 more outcomes

Companies that use Medtech AI

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Medtech AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Medtech AI partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, minor and major.

  • UK National Health System (NHS)coreStrategic or Co-development PartnerNHS co-developed and tested the Algocyte handheld finger-prick diagnostic device. This partnership provides regulatory validation and clinical testing environment for the immune health monitoring platform.
  • UK Hematology Market LeadercoreChannel Partner/ Reseller/ DistributorUK reseller partner and leader in the hematology market in the UK, holding approximately 1/3 of the market share. This partnership provides established distribution channels in the UK healthcare market.
  • Surrey Intelligent Home SystemminorStrategic or Co-development PartnerTen houses to open in Q1 2021 in Surrey with Algocyte embedded in the intelligent home system, representing integration of health monitoring into residential environments.
  • HUB71majorStrategic or Co-development PartnerOIA UAE branch sponsored by UAE committed to invest and grow the company as a hub for Asia, Africa and the Middle East. Signed collaboration agreement with medical university (KIC). This represents a major international expansion initiative.
  • Creative Destruction LabmajorStrategic or Co-development PartnerOIA was among 3 finalists among 400 startups in Creative Destruction Lab's US program. Medtech AI issued Letter of Intent to invest up to $6M in OIA over the next 2 years. Pam Winsor, CMO of Medtronic, joining the board.
  • Lacuna Diagnostics (China)majorStrategic or Co-development PartnerLeading IT remote/mobile healthcare solution provider in China covering 1,000 hospitals with over 600 million patient visits per year and 1.5 million doctors. Letter of Intent signed requesting 3,000 devices initially.
  • Lacuna Diagnostics (US)majorStrategic or Co-development PartnerServicing 40 hospitals in the US. Terms agreed to integrate Algocyte in their pathology pathway offerings.
  • SpinLab - The HHL AcceleratorminorStrategic or Co-development PartnerSpinLab's and Leipzig's commercial partners and support to open European branch. Agreement with the Leipzig zoo to test technology applied to veterinary applications.
  • KIC (Medical University)minorStrategic or Co-development PartnerMedical university in UAE with signed collaboration agreement, part of the HUB71 hub ecosystem for Asia, Africa and Middle East expansion.
  • Etihad Group FinancemajorStrategic or Co-development PartnerEtihad Group Finance (owner of Etihad Airlines) held AI international competition with partners HUB71 and Accenture. OIA won the competition and will implement forecasting platform for Etihad's Aviation Group at global scale. Prize of $10,000 USD awarded.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Medtech AI competitors and assessment

Company assessment

Direct peers

  • Tasso Inc. Tasso produces at-home blood-collection devices paired with remote lab testing, addressing the same workflow as Algocyte — patient-friendly capillary sampling followed by connected diagnostic processing.
  • Healthy.io: Healthy.io turns smartphone cameras into clinical-grade diagnostic readers (e.g., urinalysis, wound care). It is comparable to Algocyte in delivering clinical-grade diagnostics through a consumer/patient-friendly connected device format.
  • Cue Health: Cue Health builds a handheld molecular diagnostic device for at-home and clinical use, with a portable reader and connected platform. It is the closest publicly comparable to Algocyte in form factor, connected-diagnostics business model, and enterprise-plus-consumer GTM.
  • Everlywell: Everlywell offers at-home sample collection kits with connected lab testing for a panel of conditions. It competes with Algocyte on multi-condition at-home diagnostics, though Everlywell relies on mailed samples rather than an in-home reader.
  • Babson Diagnostics: Babson has developed a finger-prick blood collection and diagnostics ecosystem aimed at retail and clinical settings. It competes with Algocyte on miniaturization of blood-based diagnostics and on retail/clinical partnerships.
  • Yourbio Health: Yourbio Health (formerly Seventh Sense Biosystems) developed the TAP device for virtually painless capillary blood collection, targeting decentralized diagnostics and remote clinical trials — overlapping with Algocyte's finger-prick remote-diagnostic value proposition.
  • Oxford Immune Algorithmics (OIA): OIA is the operating company that created Algocyte and the scientific entity in which MedTechAI holds a 28% stake. It is the most direct comparable because the underlying technology, product, and pipeline are the same; MedTechAI is essentially an investment vehicle into OIA.

Broad incumbents

  • Roche Diagnostics: Roche Diagnostics is a global leader in clinical diagnostics, including POC and immunoassay platforms. It is a broad incumbent with overlapping capability in immune and infectious-disease testing that Algocyte must compete against or partner with for hospital adoption.
  • Abbott Diagnostics: Abbott Diagnostics offers extensive POC and immunoassay product lines (e.g., i-STAT, Binax) and deep hospital distribution globally. It represents the type of entrenched incumbent MedTechAI/OIA must displace or co-exist with in the POC diagnostics market.

Emerging players

  • SiPhox Health: SiPhox Health is building an at-home protein and hormone diagnostic platform with a connected reader. It targets a similar multi-biomarker home-diagnostic thesis to Algocyte, though at an earlier stage of commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Medtech AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medtech AI leadership team

Management profile

Number of profiles

Profiles4 records

Medtech AI funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medtech AI M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medtech AI

What does Medtech AI do?

MedTechAI commercializes the Algocyte handheld finger-prick diagnostic device co-developed with the UK NHS, paired with a portable web-based AI platform that monitors the user's immune system for rapid early detection of over 20 health diseases and conditions. The system delivers personalized and predictive medicine via causal predictive algorithms originated at Karolinska, incubated at the University of Oxford, and co-developed with the University of Cambridge.

Is Medtech AI a public or private company?

Medtech AI is a private company. It is classified as corporate owned and is currently operating.

When was Medtech AI founded?

Medtech AI was founded in -1.

Where is Medtech AI based?

Medtech AI is headquartered in Toronto, Canada, in the North America region.

How does Medtech AI make money?

Two revenue lines are on record. Algocyte Device Sales are the primary driver. The others are platform/Subscription Services.

Who are Medtech AI's main competitors?

Direct peers on record are Tasso Inc., Healthy.io, Cue Health, Everlywell, Babson Diagnostics, Yourbio Health and Oxford Immune Algorithmics (OIA). Broad incumbents are Roche Diagnostics and Abbott Diagnostics. SiPhox Health is listed as an emerging player.

Does Medtech AI have an API?

No public API is recorded for Medtech AI.

What industry is Medtech AI in?

Medtech AI's product category is Medical Diagnostic Devices. Its primary akta.pro industry code is HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices), with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals